Meeting
2019 ASCO Annual Meeting
A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.
Authors
Takeo Fujii
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Takeo Fujii , Hiroko Masuda , Yee Chung Cheng , Fei Yang , Aysegul A. Sahin , Yasuto Naoi , Yuki Matsunaga , Akshara Singareeka Raghavendra , Arup Kumar Sinha , Jose R. Espinosa Fernandez , Anjali James , Keisuke Yamagishi , Tomoko Matsushima , Debu Tripathy , Sachiyo Tada , Rubie S. Jackson , Shinzaburo Noguchi , Seigo Nakamura , Jared David Acoba , Naoto T. Ueno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 542)
DOI
10.1200/JCO.2019.37.15_suppl.542
Abstract #
542
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.
First Author: Ciara Marie Kelly
Poster
2013 ASCO Annual Meeting
Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.
First Author: Yi Zhang
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde